恩瑞格治疗铁质积聚的疗效怎么样？

(Deferasirox) is clinically used for patients with iron accumulation due to long-term blood transfusion (such as those suffering from thalassemia or other rare anemias). It is a new type of ferric iron chelator with high oral absorption rate. The drug metabolism half-life is 8 to 16 hours. It reaches the blood peak at 24 hours. The concentration reaches a stable state after 3 days. After metabolism, it is mainly excreted in the feces.

So, how effective is Enrig in treating iron accumulation?

Therapeutic effects of Enrige in treating iron accumulation:

Analyze the effect of Enrige dispersible tablets in the treatment of children with severe β-thalassemia iron overload.

Methods: 46 children with iron overload caused by β-thalassemia major who were admitted to our hospital from October 2015 to October 2017 were selected and divided into the Enrig group and the deferoxamine group according to the random number table method, with 23 cases in each group. The Enrig group was treated with oral Enrig dispersible tablets, while the deferoxamine group was treated with subcutaneous pump infusion of deferoxamine. The disease control effect after 1 year of medication, serum iron (SI), ferritin (SF), brain natriuretic peptide (BNP), troponin I (cTnI) and urinary ferritin (UF) levels before and after medication, liver and heart MRI T2* values ​​before and after medication, and adverse drug reactions were compared between the two groups.

Results: The disease control rate in the Enriga group was 100%, which was higher than the 78.26% of the deferoxamine group (word 2=5.610, P=0.018); after treatment, the serum SI, SF, BNP and cTnI levels of the Enriga group were lower than those of the deferoxamine group, and UF levels, liver and heart MRI were lower than those of the deferoxamine group. The T2 values were all higher than those in the deferoxamine group, and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the Enriga group was lower than that in the deferoxamine group (P<0.05).

Conclusion: Dispersible tablets have a better disease control effect than deferoxamine in the treatment of children with severe β-thalassemia iron overload. It can effectively reduce serum SI, SF, BNP and cTnI levels, reduce the load of iron overload on the liver and heart, and is safe.